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Obesity Alters Endoxifen Plasma Levels 
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Endoxifen is one of the most important metabolites of the prodrug tamoxifen. High interindividual variability in 
endoxifen steady-state concentrations (CSS,min ENDX) is observed under tamoxifen standard dosing and patients with 
breast cancer who do not reach endoxifen concentrations above a proposed therapeutic threshold of 5.97 ng/mL 
may be at a 26% higher recurrence risk compared with patients with endoxifen concentrations exceeding this value. 
In this investigation, 10 clinical tamoxifen studies were pooled (1,388 patients) to investigate influential factors on 
CSS,min ENDX using nonlinear mixed-effects modeling. Age and body weight were found to significantly impact CSS,min 
ENDX in addition to CYP2D6 phenotype. Compared with postmenopausal patients, premenopausal patients had a 
30% higher risk for subtarget CSS,min ENDX at tamoxifen 20 mg per day. In treatment simulations for distinct patient 
subpopulations, young overweight patients had a 3.1–13.8-fold higher risk for subtarget CSS,min ENDX compared 
with elderly low-weight patients. Considering ever-rising obesity rates and the clinical importance of tamoxifen for 
premenopausal patients, this subpopulation may benefit most from individualized tamoxifen dosing.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Large interindividual variability in concentrations of ta-
moxifen’s most active metabolite endoxifen is observed during 
standard breast cancer tamoxifen treatment. Minimal steady-
state endoxifen concentrations have been suggested below 
which the risk for breast cancer recurrence and mortality is 
increased. The influence of age and body weight on endoxifen 
concentrations is not well-established.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What is the quantitative impact of age and body weight on 
the pharmacokinetics (PKs) of tamoxifen and endoxifen be-
yond the patients’ genetically determined CYP2D6 tamoxifen 
metabolizer capacity?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 Age and body weight contribute to the PKs of tamoxifen 
and endoxifen in that young and overweight patients are at in-
creased risk to not achieve sufficient endoxifen concentrations.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Obese premenopausal patients may benefit most from in-
dividualized tamoxifen dosing, particularly in the case of an 
intact genetically determined tamoxifen drug metabolism. If 
their CYP2D6 function is impaired, alternative endocrine 
treatment of ovarian function suppression combined with aro-
matase inhibitors should be considered.
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Tamoxifen treatment for 5–10 years is widely used in premeno-
pausal and an option in postmenopausal patients with estrogen 
receptor positive breast cancer.1,2 During its use for >  40  years, 
a 5-year adjuvant tamoxifen treatment has been proven to effec-
tively reduce breast cancer recurrence by around 30% in the first 
15 years of therapy.3 Tamoxifen is extensively metabolized and 
considered to be the pro-drug to its 100-fold more active metabo-
lite endoxifen.4,5
Several polymorphic enzymes, such as CYP2D6, 
CYP2C9, CYP2C19, CYP3A5, sulfotransferases, and UDP-
glucuronosyltransferases, are involved in tamoxifen metabo-
lism5,6 and consequently large interindividual variability (IIV) 
in endoxifen minimum concentrations at steady-state (CSS,min 
ENDX) has been observed under tamoxifen standard dosing 
(20  mg once daily (q.d.)).7–9 CYP2D6 is especially import-
ant for endoxifen formation and patients with impaired or no 
CYP2D6 activity have shown an increased risk for subtarget 
CSS,min ENDX.
8–11 Regarding a putative therapeutic threshold 
concentration, Madlensky et al. reported that patients with 
CSS,min ENDX < 5.97 ng/mL had a 26% higher breast cancer re-
currence rate compared with patients with CSS,min ENDX above 
this threshold (recurrence rates 16% vs. 10.1–14.7%).9 This dif-
ference is similar to the reported 30% relative reduction in breast 
cancer recurrence rates, when postmenopausal patients receive 
aromatase inhibitors instead of tamoxifen.12 The aforemen-
tioned target concentration was later supported by Saladores et 
al. for premenopausal patients.8 Other studies failed to find the 
described relationship between CSS,min ENDX and/or CYP2D6 
and treatment outcome,13–15 which might, in part, be due to 
heterogeneous patient populations, study designs, DNA source 
used for CYP2D6 genotype determination,7,16 and insufficient 
power to detect the relationships.17,18 Accordingly, the efficacy 
of breast cancer tamoxifen treatment may be influenced by the 
proposed target threshold, however, nongenetic factors be-
yond CYP2D6 functionality, influencing the pharmacokinetics 
(PKs) of tamoxifen and endoxifen may play a role. Of those, a 
positive correlation between patient age and tamoxifen concen-
trations has been described in literature19–21 and was later quan-
tified and found to be clinically relevant in a PK analysis using 
nonlinear mixed-effects modeling.22 Furthermore, increased 
body weight or body mass index (BMI) have been associated 
with decreased concentrations of tamoxifen and its primarily 
lipophilic metabolites8,9,19,23 and worse clinical outcome.24,25 
However, the impact of body weight on CSS,min ENDX has never 
been quantified.
In this work, we applied mathematical modeling and simulations 
to quantify the influence of age and body weight on CSS,min ENDX in 
patients treated with tamoxifen and report a patient subpopulation 
at risk for subtarget endoxifen concentrations.
METHODS
Clinical study database
A large tamoxifen clinical study dataset was compiled by pooling data 
from 10 clinical studies. Studies 1–626–30 (referred to as “development 
dataset,” previously pooled at the Freie Universitaet Berlin, Germany) 
and studies 7–108,10 (referred to as “evaluation dataset,” previously pooled 
at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology 
in Stuttgart, Germany) are described in detail elsewhere.10,22 All stud-
ies were conducted in accordance with the ethical standards of the 
Declaration of Helsinki and had been approved by the respective ethics 
committees.
The pooled dataset comprised demographic, PK and pharmacogenetic 
data, and tamoxifen and endoxifen steady-state (SS) plasma concentrations 
in 1,388 female patients with breast cancer receiving 20 mg (n = 1,373) 
or 40 mg (n = 15) tamoxifen once daily (q.d.; Table 1). Tamoxifen and 
endoxifen concentrations were analyzed in plasma or serum using liquid 
chromatography linked with tandem mass spectrometry (detailed infor-
mation in Supplementary Tables S1 and S2). As studies were conducted 
independently from each other, no cross-validation between laboratories 
was performed. Patients receiving strong CYP2D6 inhibitors or CYP3A4 
inducers and patients who had not yet reached SS were excluded from the 
development dataset (n = 16) prior to pooling.
According to the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guideline for CYP2D6 and Tamoxifen Therapy, 
patients were assigned CYP2D6 activity scores (AS) based on their 
CYP2D6 diplotypes.31 Genotype-predicted phenotype assignment 
was as follows: (i) AS of 0 refers to poor metabolizers (gPM), (ii) AS of 
0.5–1 refers to intermediate metabolizers (gIM), and (iii) AS of ≥ 1.5 
refers to normal metabolizers (gNM; including ultrarapid-metabolizers 
(AS  >  2)).32 For patients with missing genotype information (n  =  39, 
2.81%) the CYP2D6 wildtype (AS = 2) as most frequent CYP2D6 AS 
was imputed.
Menopausal status had not been reported in the development dataset 
and was imputed for patients with missing information based on the in-
tersection of the age densities for premenopausal and postmenopausal pa-
tients in the evaluation dataset (52 years, in line with the definition used 
by the North American Menopause Society33). The development dataset 
included white (n = 433) and African (n = 2) patients, whereas the evalu-
ation dataset included premenopausal and postmenopausal white patients 
(n = 681) and premenopausal Africans (n = 12), Middle-Eastern Arabs 
(n = 77), Asians (n = 153), and Indians (n = 12). For patients without 
reported ethnicity (n = 14, 1.01%), white ethnicity, as the most frequent, 
was imputed.
Joint parent-metabolite PK model of tamoxifen and 
endoxifen, and external model evaluation
The joint parent-metabolite nonlinear mixed-effects modeling PK 
model of tamoxifen and endoxifen developed using the development 
dataset22 was externally evaluated using the evaluation dataset. A 
one-compartment model—parameterized in terms of relative clear-
ances (CL/F) and volumes of distributions, with first-order absorption 
with lag time for tamoxifen—was linked to an endoxifen one-com-
partment model via a linear first-order formation process (CL23/F). 
Elimination of both tamoxifen and endoxifen (CL20/F and CL30/F, 
respectively) were described as linear first-order processes. Parameter 
values for endoxifen apparent clearance (CL30/F) and endoxifen ap-
parent volume of distribution (VENDX/F) were adopted from a study in 
which endoxifen had been administered as a single compound.34 IIV 
parameters were estimated for both tamoxifen clearance and endoxi-
fen formation (CL20/F and CL23/F, respectively), whereas interocca-
sion variability was not considered, as only one PK sample per patient 
was available in the evaluation dataset. CYP2D6 AS and age as sig-
nificant covariates on endoxifen formation and tamoxifen clearance, 
respectively, were implemented as proportional and power functions, 
respectively.
Based on the final estimates using the development dataset, tamoxifen 
and endoxifen concentrations were predicted for the evaluation dataset 
and compared with observed concentrations. Mean absolute prediction 
errors and mean prediction errors were calculated to assess precision and 
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bias, respectively.35 Finally, model parameters, except absorption param-
eters, which were fixed to the estimates obtained during model develop-
ment as the evaluation dataset contained CSS,min only, were re-estimated 
using the pooled dataset and compared with previously estimated parame-
ters using the development dataset.
Extensive covariate analysis and final model development
Patient characteristics were preselected for the extensive covariate anal-
ysis based on physiological plausibility, previous literature reports, and 
sufficient information in the pooled dataset. A relationship between in-
creasing age and decreasing tamoxifen clearance had been reported21 and 
was supported by our previous analysis using the development dataset.22 
To evaluate this relationship in the pooled dataset and test for differences 
between both datasets, CSS,min ENDX were compared between premeno-
pausal and postmenopausal patients receiving 20  mg tamoxifen q.d. in 
the development (n = 435) and evaluation (n = 935) datasets, respectively. 
Based on expected PK differences between ethnicities,36 CSS,min ENDX 
were additionally compared between premenopausal patients of different 
ethnicities in the evaluation dataset. To evaluate the contribution of vary-
ing CYP2D6 phenotype frequencies to the observed differences between 
ethnicities, CSS,min ENDX were compared in premenopausal patients of 
different ethnicities stratified for CYP2D6 phenotype.
To assess if differences between patient subpopulations were statis-
tically significant, nonparametric Wilcoxon tests were performed. The 
extensive covariate analysis was based on the pooled dataset and the 
original PK base model. Age, CYP2D6 AS, and newly selected covari-
ates, body weight as proportional or power function, and ethnicity as 
categorical, function were tested for significance on model parameters 
endoxifen formation (CL23/F), endoxifen clearance (CL30/F), and 
tamoxifen clearance (CL20/F) using stepwise covariate model-build-
ing.37 Significance criteria of 3.84 (α  =  0.05) and 7.88 (α  =  0.005) 
points change in objective function value were applied in the inclusion 
and exclusion steps, respectively. Finally, goodness-of-fit plots were cre-
ated to assess model performance.
Treatment simulations for different patient subpopulations
Applying the updated joint parent-metabolite PK model with its final pa-
rameter estimates, treatment simulations were performed to investigate 
the impact of age and body weight on achieving target CSS,min ENDX under 
tamoxifen standard dosing. In two separate simulation study set-ups, 14 
large virtual patient populations (n = 10,000 each) with CYP2D6 AS 
frequencies extrapolated from the pooled dataset and different age and 
body weight ranges or combinations thereof were generated:
Study set-up 1: Endoxifen subtarget concentrations for subpop-
ulations with different age and body weight distributions. Study 
set-up 1 (SU1) was based on the observed distributions of age and body 
weight in the pooled dataset. Achievement of target CSS,min ENDX was 
compared between patients with low or high covariate values (less than 
the first quartile and greater than the third quartile, respectively) and 
patients with covariate values in the interquartile range of the covari-
ate value distribution in the pooled dataset (“reference subpopulation”; 
in total: 7 patient populations; Table 2). Specifically, for each virtual 
patient, an age and body weight value were sampled independently 
with replacement from the respective section (e.g., less than the first 
quartile) of the covariate value distribution in the pooled dataset.
Study set-up 2: Endoxifen subtarget concentrations for subpopu-
lations with extreme age and body weight values. In study set-up 
2 (SU2), CSS,min ENDX target attainment was compared between virtual 
patients with minimum or maximum covariate values and patients with 
median covariate values in the pooled dataset (“reference subpopulation”; 
in total: 7 patient populations; Table 2).
Table 1 Clinical study and population characteristics of the development, evaluation, and pooled dataset at baseline
Characteristic Development dataset Evaluation dataset Pooled dataset
Number of patients 452 936 1,388
Age [years] Median (range) 64 (25–95) 48 (22–84) 55 (22–95)
Body weight [kg] Median (range) 70 (42–150) 
8.85% n.r.
66 (39–144) 
2.03% n.r.
67 (39–150) 
4.25% n.r.
Fraction of heavy or light patients  
(as defined in SU1)
19.9% Light 
31.8% Heavy
31.3% Light 
23.3% Heavy
27.8% Light 
26.0% Heavy
Frequency of CYP2D6 genotype-
predicted phenotypes (according to 
ref. 32)
53.5% gNM 
34.5% gIM 
5.53% gPM 
6.42% n.r.
54.0% gNM 
39.4% gIM 
5.56% gPM 
1.07% n.r.
53.8% gNM 
37.8% gIM 
5.55% gPM 
2.81% n.r.
Ethnicity 97.4% White 
0.44% African 
2.21% n.r.
72.4% White 
1.28% African 
16.4% Asian 
8.23% Middle–Eastern Arab 
1.28% Indian 
0.43% n.r.
80.6% White 
0.87% African 
11.0% Asian 
5.55% Middle–Eastern Arab 
0.87% Indian 
1.01% n.r.
Menopausal status 100% n.r. 60.0% Pre–menopausal 
39.0% Post–menopausal 
1.0% n.r.
41.0% Pre–menopausal 
26.3% Post–menopausal 
32.7% n.r.
Treatment setting 41.6% Adjuvant 
13.1% Neo–Adjuvant 
22.1% Primary metastatic 
21.5% Metastatic 
1.7% n.r.
100% Adjuvant 81.0% Adjuvant 
4.25% Neo–Adjuvant 
7.20% Primary metastatic 
6.99% Metastatic 
0.58% n.r.
PK sampling design Sparse & dense Sparse Sparse and dense
gNM, gIM, gPM, genotype-predicted CYP2D6 normal (including ultrarapid), intermediate and poor metabolizer; n.r., not reported; PK, pharmacokinetic(s); SU1, 
study setup 1.
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To account for parameter uncertainty, 1,000 simulations using 
bootstrapped parameter sets were performed for each subpopula-
tion and the 50th, 5th, and 95th percentiles were used to determine 
medians and 90% confidence intervals (CIs), respectively, of (i) the 
fraction of patients of the respective subpopulation at risk for CSS,min 
ENDX target nonattainment, (ii) the absolute change in risk compared 
with the respective reference subpopulation, (iii) the relative change 
in risk compared with the respective reference subpopulation, and (iv) 
the number needed to treat/harm (NNT/NNH), defined as 1 divided 
by the absolute change in risk, compared with the respective reference 
subpopulation. Thus, the ratio described the NNH if the absolute 
change in risk was positive, and the NNT if the absolute change in risk 
was negative. Finally, for the two patient populations that had shown 
the highest risk for subtarget CSS,min ENDX in SU1 and SU2, CSS,min 
ENDX at alternative daily tamoxifen doses of 40  mg and 60  mg were 
simulated and medians and 90% CIs of the fractions of patients at risk 
for subtarget CSS,min ENDX were calculated.
RESULTS
External model evaluation
The original joint-parent metabolite population PK model of tamox-
ifen and endoxifen performed well for the evaluation dataset: mean 
prediction errors indicated a low bias for tamoxifen (−13.9 ng/mL) 
and a minimal bias for endoxifen (−0.923  ng/mL). Precision was 
acceptable for both tamoxifen and endoxifen, as indicated by 
MAPEs < 8% (7.62% and 6.29%, respectively).38 After parameter 
re-estimation using the pooled dataset, all fixed (structural and co-
variate) parameter estimates remained comparable except the tamox-
ifen clearance CL20/F for a typical (AS 2, median age 55  years) 
patient (development dataset: 6.51 L/h (2.4% relative standard error 
(RSE)), pooled dataset: 5.08 L/h (1.1% RSE), and the exponent for 
the typical age effect on the tamoxifen clearance (development data-
set: −0.844 (10.0%), pooled dataset: −0.148 (24.0%)). Furthermore, 
estimated IIV values on CL20/F and CL23/F were slightly lower 
(40.4% vs. 41.5% and 46.1% vs. 49.2%, respectively) for the pooled 
dataset compared with the development dataset.
Extended covariate analysis and final model development
A significant difference between CSS,min ENDX in premeno-
pausal (n  =  67) and postmenopausal (n  =  368) patients was 
observed in the development dataset (97.4% white patients; 
Table S3): whereas 29.9% of premenopausal patients showed 
subtarget CSS,min ENDX  <  5.97  ng/mL, it was only 20.1% of 
postmenopausal patients (Table 3). Conversely, in the evalu-
ation dataset, with 18.8% and 18.0% of patients with subtar-
get CSS,min ENDX (Table 3), there was no difference in CSS,min 
ENDX between premenopausal (n  =  568) and postmenopausal 
(n  =  367) patients (Table S3). However, after stratifying pa-
tients in the evaluation dataset for their ethnicity, a highly 
significant difference between CSS,min ENDX in premenopausal 
and postmenopausal white patients became apparent (Tables 3 
and S3). Furthermore, there were large differences between 
CSS,min ENDX, ascending from premenopausal Africans, whites, 
Middle-Eastern Arab, and Asian to Indian patients (Table S3). 
Indians, Asians, and Middle-Eastern Arabs showed the low-
est number of patients with subtarget CSS,min ENDX (0%, 5.8%, 
and 13.0%, respectively) whereas Africans and white patients 
showed the highest (50.0% and 26.1%, respectively). Of note, 
relative risk reductions due to transition from premenopause to 
postmenopause were 32.8% in the development dataset (n = 433 
whites, n = 2 Africans), 4.26% for the evaluation dataset with-
out stratification for ethnicity (n  =  935) and 31.0% for white 
patients in the evaluation dataset (n = 681; no further analysis 
was possible as no data from postmenopausal patients of other 
ethnicities were available). Upon stratification for CYP2D6 
phenotype, the differences in CSS,min ENDX between premeno-
pausal patients of different ethnicities remained. Further ex-
ploratory analyses revealed a correlation between body weight 
and ethnicity in the evaluation dataset. Body weight was 
highest in premenopausal Middle-Eastern Arabs, followed by 
whites, Africans, Indians, and Asians (Table S4). Furthermore, 
patients of ethnicities with low body weights demonstrated a 
lower risk for subtarget CSS,min ENDX compared with patients 
of ethnicities with high body weights (Figures S1 and S2). 
Subsequently, both ethnicity and body weight were tested for 
significance on CL20/F, CL23/F, and CL30/F in the extended 
covariate analysis.
Covariate relationships of CYP2D6 AS on CL23/F (categori-
cal), age and body weight on CL20/F (both power functions), and 
ethnicity on CL20/F (categorical) were all significant in univari-
ate analyses. Including ethnicity on CL20/F in addition to body 
weight, however, did not further improve model predictions. Due 
Table 2 Covariate values used in simulating 14 different patient subpopulations (seven per study-setup) (see main text for 
detailed explanations of study set-ups 1 and 2)
Subpopulation (n = 10,000 each)
Study-setup 1 Study-setup 2
Age, years Body weight, kg Age, years Body weight, kg
Heavy young 22–39 (<Q1) 77–150 (>Q3) 22 (Min.) 150 (Max.)
Young 22–39 (<Q1) 60–76 (IQR) 22 (Min.) 68 (Med.)
Heavy 40–65 (IQR) 77–150 (>Q3) 55 (Med.) 150 (Max.)
IQR/Median (Reference) 40–65 (IQR) 60–76 (IQR) 55 (Med.) 68 (Med.)
Elderly 66–95 (>Q3) 60–76 (IQR) 95 (Max.) 68 (Med.)
Light 39–60 (<Q1) 40–65 (IQR) 55 (Med.) 39 (Min.)
Light elderly 66–95 (>Q3) 39–60 (<Q1) 95 (Max.) 39 (Min.)
Contents of the brackets indicate which part of the covariate distribution in the pooled dataset is represented.
IQR, interquartile range; Max., maximum; Med., median, Min., minimum; Qx., Quartile with x = 1–3.
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to the stronger physiological plausibility, body weight remained 
and ethnicity was excluded as covariate on CL20/F in the final 
model. Thus, the updated full covariate model (schematic rep-
resentation in Figure 1) included three covariate relationships: 
CYP2D6 AS on CL23/F and age and body weight on CL20/F 
(final parameter estimates and their RSEs in Table 4). The pop-
ulation estimate for the power exponent of age was −0.17 (RSE: 
21%), thus the tamoxifen clearance was estimated to moderately 
decrease with increasing age. In contrast, the population estimate 
for the power exponent of body weight was 0.284 (RSE: 19%), 
indicating a moderately increasing clearance with increasing body 
weight. With RSE ≤ 28%, all model parameters were estimated with 
good precision. goodness-of-fit plots showed good model perfor-
mance in predicting observed individual tamoxifen and endoxifen 
concentrations (Figure S3).
Treatment simulations for different patient subpopulations
Study set-up 1: Endoxifen subtarget concentrations for 
subpopulations with different age and body weight distributions. 
Up to 3.1-fold differences in reaching target CSS,min ENDX were 
observed between patient subpopulations in SU1 (Figure 2, 
Table S5): heavy young patients (<  40  years, >  76  kg) showed 
the highest risk for subtarget CSS,min ENDX (36.9%, 90% CI: 
34.6–39.2%), whereas light elderly patients (> 65 years, < 60 kg) 
showed the lowest risk (12.1%, 90% CI: 10.8–13.4%). gIMs were 
most sensitive to changes in covariate values: whereas the NNH Ta
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Figure 1 Schematic representation of the joint tamoxifen (TAM) 
and endoxifen (ENDX) pharmacokinetic model and the implemented 
covariate relationships. CL30/F, relative clearance of endoxifen; 
CL20/F, relative clearance of tamoxifen; CL23/F, relative formation 
of endoxifen; CYP2D6 activity score (AS), CYP2D6 activity scores 
as ordered categorical covariate from 0 to ≥ 2 in increments of 0.5; 
ENDX, endoxifen compartment with VENDX/F; ka, absorption rate 
constant; Gut, tamoxifen dose in gut compartment; TAM, central 
tamoxifen compartment with VTAM/F; tlag, lag time; bold: estimated 
parameters (other parameters fixed to values from literature34). ka, tlag, 
VTAM/F: fixed to estimates using the development dataset (with rich 
sampling data). [Colour figure can be viewed at wileyonlinelibrary.com]
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for heavy young gNMs and gPMs was 8 and 9, respectively, it was 
5 in gIMs (Table S6).
Study set-up 2: Endoxifen subtarget concentrations for 
subpopulations with extreme age and body weight values. The 
patterns observed in SU1 were expectedly even stronger in SU2: 
up to 13.8-fold differences in CSS,min ENDX target attainment were 
observed between heavy young (22 years, 150 kg) and light elderly 
(95 years, 39 kg) patients (70.6%, 90% CI: 66.2–75.1% vs. 5.10%, 
90% CI: 4.18–6.22% of patients at risk, respectively; Figure 3, 
Table S7). NNH were again lowest in heavy young patients (2 for 
gNMs and gIMs, 6 for gPMs; Table S8).
In both study set-ups, the impact of body weight on endox-
ifen CSS,min ENDX was more pronounced than the impact of age, 
as displayed by the lower relative risk increase in young patients 
(median: +13.0%, 90% CI: 6.50–19.4%) compared with heavy 
patients (median: +58.1%, 90% CI: 49.8–66.8%) when compared 
with the reference subpopulation in SU1.
As heavy young patients showed the highest risk for subtarget 
CSS,min ENDX in both study set-ups, CSS,min ENDX target attainment 
at 40 mg and 60 mg tamoxifen q.d. was assessed for this subpopu-
lation in both SU1 and SU2 (Supplementary Figures S4 and S5).
In SU1, 40  mg tamoxifen q.d. were sufficient to reduce the 
fraction of patients with subtarget CSS,min ENDX from 36.9% to 
10.6% (90% CI: 9.44–11.8%). This fraction varied substantially 
among CYP2D6 phenotypes (3.06% for gNMs, 14.2% for gIMs, 
and 62.0% for gPMs). In SU2, 40 mg tamoxifen q.d. reduced the 
fraction of patients with subtarget CSS,min ENDX from 70.6% to 
Table 4 Final parameter estimates for the updated joint parent-metabolite population pharmacokinetic model of tamoxifen 
and endoxifen using the pooled dataset (1,388 patients)
Parameter (unit) Parameter description Estimate RSE, %
Fixed effects
ka (1/hour) Absorption rate constant 1.08 Fixed
tlag (hour) Absorption lag time 0.442 Fixed
VTAM/F (L) Tamoxifen apparent volume of distribution 912 Fixed
CL30/F (L/hour) Apparent endoxifen clearance 5.10 Fixed
VENDX/F (L) Endoxifen apparent volume of distribution 400 Fixed
CL20/F (L/hour) Apparent tamoxifen clearance 5.07 1
CL20/F_Agea Exponent for the covariate effect of age on the 
apparent tamoxifen clearance
−0.17 21
CL20/F_Body weighta Exponent for the covariate effect of body weight on 
the apparent tamoxifen clearance
0.284 19
CL23/F (L/hour) Apparent endoxifen formation for an AS of 2 0.459 2
CL23/F_AS: 0b Fractional change in the apparent endoxifen 
formation for an AS of 0
−0.759 2
CL23/F_AS: 0.5b Fractional change in the apparent endoxifen 
formation for an AS of 0.5
−0.598 4
CL23/F_AS: 1b Fractional change in the apparent endoxifen 
formation for an AS of 1
−0.347 6
CL23/F_AS: 1.5b Fractional change in the apparent endoxifen 
formation for an AS of 1.5
−0.16 18
CL23/F_AS: 2.5–3b Fractional change in the apparent endoxifen 
formation for an AS of > 2
0.302 28
Random effects
IIV CL20/F Interindividual variability in the apparent tamoxifen 
clearance
0.148 (39.9% CV) 5
IIV CL23/F Interindividual variability in the apparent endoxifen 
clearance
0.192 (46.0% CV) 5
RUV tamoxifen Residual unexplained variability in the observed 
tamoxifen concentrations
0.0295 (17.3% CV) 11
COVRUVtam-RUVendx Correlation between RUV tamoxifen and RUV 
endoxifen
0.0228 7.28
RUV endoxifen Residual unexplained variability in the observed 
endoxifen concentrations
0.037 (19.4% CV) 7
AS, CYP2D6 activity score; CL20/F, apparent tamoxifen clearance; CL23/F, apparent endoxifen formation; CL30/F, apparent endoxifen clearance; IIV, 
interindividual variability; ka, absorption rate constant; RUV, residual unexplained variability; RSE, relative standard error = (standard error/estimate)·100; tlag, 
absorption lag time; VTAM/F, tamoxifen apparent volume of distribution; VENDX/F, endoxifen apparent volume of distribution.
 aImplemented as power covariate model (detailed description in ref. 23). bImplemented as fractional change covariate model (detailed description in ref. 23).
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32.2% (90% CI: 27.9–36.9%). When the analysis was stratified for 
CYP2D6 phenotype, 18.1% of gNMs, 44.7% of gIMs, and 90.6% 
of gPMs remained at subtarget CSS,min ENDX.
At 60  mg tamoxifen q.d., 4.10% (90% CI: 3.48–4.77%) and 
15.8% (90% CI: 13.2–18.9%) of patients still showed subtarget 
CSS,min ENDX in SU1 and SU2, respectively. When stratified for 
CYP2D6 phenotype, 0.600% of gNMs, 4.63% of gIMs, and 36.2% 
of gPMs showed subtarget CSS,min ENDX in SU1 whereas it was 
5.83% of gNMs, 22.3% of gIMs, and 74.4% of gPMs in SU2.
DISCUSSION
We identified young overweight patients with breast cancer as 
a subpopulation at increased risk for subtarget endoxifen levels 
during adjuvant tamoxifen treatment. This finding is of potential 
clinical relevance because premenopausal patients with breast can-
cer highly depend on the efficacy of tamoxifen given that ovarian 
function suppression in combination with an aromatase inhibitor 
can only be considered for a small portion of high-risk patients. 
Therefore, every effort needs to be made to increase tamoxifen ef-
ficacy, particularly in those patents with an intact CYP2D6 func-
tion for sufficient endoxifen formation.
The strength of our study is its large cohort size of 1,388 pre-
menopausal and postmenopausal tamoxifen-treated patients with 
breast cancer with a wide body weight range (39–150  kg). This 
allowed us to reliably identify and quantify the influence of body 
weight on endoxifen SS concentration in addition to the impact of 
CYP2D6 function.
Of note, we informed our model parameters describing appar-
ent endoxifen volume of distribution and clearance with previously 
reported values from a phase I study.34 As no demographic details 
were disclosed, it remains unknown whether the patients in our 
pooled dataset were similar to the patients studied in this cohort. 
Thus, future investigations using endoxifen as a single compound 
should add insight into these parameter values in the relevant pa-
tient population.
Using treatment simulations to investigate CSS,min ENDX in differ-
ent patient subpopulations, young overweight patients were identi-
fied at highest risk for subtarget CSS,min ENDX. The design of SU1 was 
chosen to consider the “real-world” variability of the covariate distri-
butions and to decrease potential bias of the simulation results due 
to extreme values observed in the pooled dataset. In contrast, SU2 
assessed ultimate best-case and worst-case scenarios, as could be ex-
pected considering the covariate values observed in the pooled data-
set. The large number of 10,000 patients for each subpopulation was 
used to represent the distribution of CYP2D6 phenotypes observed 
in “real-world” populations and allowed the generation of sufficient 
numbers of virtual patients with rare CYP2D6 genotypes in each 
subpopulation. Furthermore, it allowed to represent the high IIV 
observed in real-world data. The large number of 1,000 simulations 
with bootstrapped parameter sets for each subpopulation allowed to 
additionally determine CIs for the fractions of patients at risk.
The large size of our study dataset allowed us to revise and up-
date the previously described relationship between increasing age 
and decreasing tamoxifen clearance.22 At first sight, this relation-
ship was far less pronounced in the evaluation dataset compared 
with the development dataset indicated by a higher (less nega-
tive) power exponent in the covariate relationship of tamoxifen 
clearance and age. Even though bioanalytical laboratories were 
not cross-validated and the validated analytical methods differed 
between some studies, no major differences in measured concen-
trations, which could have explained this finding, were observed 
between both datasets. The difference can rather be explained 
Figure 2 Patients at risk of subtarget endoxifen concentrations across patient subpopulations in study-setup 1 (see main text for further 
explanation) as observed in 1 of the 1,000 stochastic simulations. Simulated minimum steady-state concentrations of endoxifen (ENDX 
minimum concentration at steady state (SS)) in seven different patient populations with covariate characteristics as indicated on the right. 
Dashed horizontal line: endoxifen target threshold9; boxes: interquartile range (IQR), including median; whiskers: range from hinge to lowest/
highest value within 1.5 IQR; points: data outside whiskers.
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by different body weight distributions. Although body weight 
was similar in premenopausal and postmenopausal patients in 
the development dataset (Table S4), it was significantly lower in 
premenopausal compared with postmenopausal patients in the 
evaluation dataset (P  <  0.001). The latter might be explained 
by differences in ethnicities and cultural background. Especially 
Asian and Indian premenopausal patients had lower body weights 
compared with white individuals, who were the only ethnic group 
in postmenopausal patients.
Thus, the opposing influences of low body weight and young 
age on the tamoxifen clearance could have masked each other in 
the evaluation dataset. Supporting this hypothesis, relative risk re-
ductions due to the transition from premenopause to postmeno-
pause were similar in white patients of both datasets (32.8% in 
the development dataset, and 31.0% in the evaluation dataset). 
Physiological explanations for our finding of decreased tamoxifen 
and endoxifen plasma concentrations in patients with high body 
weight include either (i) an increased clearance due to increased 
body weight causing an increased liver size and function,39 or (ii) 
an increased distribution of the more lipophilic compound tamox-
ifen into fat tissue (logP-values: 7.1, 6.7, and 6.3 for tamoxifen, N-
desmethyltamoxifen, and endoxifen, respectively40–42). Decreased 
plasma concentrations of tamoxifen’s lipophilic metabolite N-
desmethyltamoxifen in patients with high BMIs compared with 
patients with low BMIs have been reported before8 and no influ-
ence of body weight on endoxifen formation and endoxifen clear-
ance was determined in our extended covariate analysis, supporting 
the latter hypothesis.
Our dose escalation simulations for young overweight patients 
clearly demonstrated that 40  mg tamoxifen q.d. were more ade-
quate for gIMs, reducing the number of patients with subtarget 
CSS,min ENDX to 14.2% in SU1. However, 44.7% of young over-
weight gIMs were still at risk in SU2. Moreover, 40 mg and even 
60 mg tamoxifen q.d. were not enough to reduce the number of 
young overweight gPMs with subtarget CSS,min ENDX below 36.2% 
and 74.4% in SU1 and SU2, respectively. From this, it follows that 
other treatment options, like aromatase inhibitors with ovarian 
function suppression, should be used for young overweight gPMs 
and obese gIMs, which is an alternative supported by prospective 
clinical data.43
Of note, 99% of the patients in our pooled dataset received 
20 mg tamoxifen q.d. Thus, simulated endoxifen concentrations 
at higher doses rely on the assumption of dose linearity. Moreover, 
increasing the dose also increases the concentrations of tamoxi-
fen and its primary metabolites, which has, in part, been associ-
ated with more frequent adverse events.44 Several studies have 
reported the feasibility and safety of tamoxifen dose escalations 
up to 120 mg q.d.45–47 However, sample sizes were small and fur-
ther information on the safety of increased tamoxifen doses has 
to be generated before their use can be recommended in clinical 
routine.
Importantly, whereas CYP2D6 AS, body weight, and age ex-
plained general trends within the population, the IIV in both 
tamoxifen clearance (39.9% coefficient of variation, RSE: 3%) 
and endoxifen formation (46% coefficient of variation, RSE: 3%) 
remained high. Thus, individual CSS,min ENDX may deviate from 
the predictions for typical patients. Moreover, we demonstrated 
in SU2 that individual risks for subtarget CSS,min ENDX can largely 
differ from the average expected risk of the respective typical pa-
tient of a specific subpopulation and strongly depend on patients’ 
individual covariate combination. Using a fixed dose could thus 
lead to subtarget CSS,min ENDX (in case of (young) obese patients) 
Figure 3 Patients at risk of subtarget endoxifen concentrations across patient subpopulations in study-setup 2 (see main text for further 
explanation) as observed in 1 of the 1,000 stochastic simulations. Simulated minimum steady-state (SS) concentrations of endoxifen (ENDX 
minimum concentration at SS) in seven different patient populations with covariate characteristics as indicated on the right. Dashed horizontal 
line: endoxifen target threshold9; boxes: interquartile range (IQR), including median; whiskers: range from hinge to lowest/highest value within 
1.5 IQR; points: data outside whiskers.
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but also unnecessary high doses (in case of (elderly) low weight 
patients, for whom we have found in our previous work22 that 
doses lower than 20 mg q.d. would be sufficient as well.
We, therefore, strongly advocate to use model-informed preci-
sion dosing to identify personaliszd tamoxifen doses for CSS,min 
ENDX target attainment
22: Based on a patient’s CYP2D6 AS, age, 
and body weight, our model can guide initial dose selection and, 
if needed, dose refinement upon availability of measured CSS,min 
ENDX. In this respect, it should be mentioned that the endoxifen 
target threshold used in this study is yet controversial. However, 
a recent report from a prospective clinical trial suggesting no re-
lationship between CYP2D6 genotype or CSS,min ENDX and treat-
ment outcome15 provoked large criticism with regard to applied 
methods18,48,49 and low statistical power.17 Thus, a properly de-
signed and well-powered prospective clinical trial17 is needed 
to assess the relationship between CYP2D6 genotype or CSS,min 
ENDX and breast cancer outcome. Provided the threshold or a 
similar clinical concentration cut-off point for endoxifen will be 
confirmed, a patient’s CYP2D6 genotype, body weight, and age 
should be considered in an individualized dose selection process to 
reach therapeutic endoxifen levels.
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